Trial Profile

Safety and Efficacy Of Recombinant Human Deoxyribonuclease Eye Drops In Patients With Sjogren's and Non-Sjogren Dry Eye Disease

Status: Discontinued

Phase of Trial: Phase I/II

Latest Information Update: 07 Nov 2019

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Dornase alfa (Primary)
Indications Dry eyes; Sjogren's syndrome
Focus Therapeutic Use

Most Recent Events

16 Oct 2019 Status changed from recruiting to discontinued.
15 Jan 2018 Planned End Date changed from 1 Dec 2017 to 1 Sep 2018.
15 Jan 2018 Planned primary completion date changed from 1 Oct 2017 to 1 Jun 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com